The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts  by Secchiero, Paola et al.
The MDM-2 Antagonist Nutlin-3 Promotes the Maturation
of Acute Myeloid Leukemic Blasts1
Paola Secchiero*, Carlotta Zerbinati*, Elisabetta Melloni y, Daniela Milani*, Diana Campioni z, Roberto Fadda*,
Mario Tiribelli§ and Giorgio Zauli*
*Department of Morphology and Embryology, University of Ferrara, Ferrara, Italy; yDepartment of Biomedicine,
University of Trieste, Trieste, Italy; zSection of Hematology, Department of Biomedical Sciences and Advanced
Therapies, University of Ferrara-Arcispedale S. Anna, Ferrara, Italy; §Division of Hematology and Bone Marrow
Transplantation, Department of Medical and Morphological Researches, University Hospital, Udine, Italy
Abstract
The small-molecule inhibitor of murine double min-
ute (MDM-2), Nutlin-3, induced variable apoptosis in
primary acute myeloid leukemia (AML) blasts and pro-
moted myeloid maturation of surviving cells, as dem-
onstrated by analysis of CD11b and CD14 surface
antigens and by morphologic examination. Although
the best-characterized activity of Nutlin-3 is activation
of the p53 pathway, Nutlin-3 induced maturation also
in one AML sample characterized by p53 deletion, as
well as in the p53/ human myeloblastic HL-60 cell
line. At the molecular level, the maturational activity
of Nutlin-3 in HL-60 cells was accompanied by the in-
duction of E2F1 transcription factor, and it was signif-
icantly counteracted by specific gene knockdown with
small interfering RNA for E2F1. Moreover, Nutlin-3,
as well as tumor necrosis factor (TNF) A, potentiated
the maturational activity of recombinant TNF-related
apoptosis-inducing ligand (TRAIL) in HL-60 cells. How-
ever, although TNF-A significantly counteracted the pro-
apoptotic activity of TRAIL, Nutlin-3 did not interfere
with the proapoptotic activity of TRAIL. Taken together,
these data disclose a novel, potentially relevant thera-
peutic role for Nutlin-3 in the treatment of both p53
wild-type and p53/ AML, possibly in association with
recombinant TRAIL.
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Introduction
The human homologue of murine double minute (MDM-2) is
an oncogene overexpressed in different types of malignan-
cies, including leukemias (reviewed in Bueso-Ramos et al.
[1]), which plays an important role in cancer development
and progression. The best-characterized biologic activity of
MDM-2 is to antagonize the transcriptional activity of p53
and to target p53 for ubiquitin-dependent proteolysis [2].
The mdm2 gene is itself transcriptionally activated by p53
in a regulatory feedback loop [3]. It is noteworthy, however,
that besides interacting with p53, the mdm2 gene encodes a
protein consisting of several domains with different functions:
1) an N-terminal domain that contains binding sites for the
transcription factors p53 and E2F1; 2) an acidic domain that
interacts with the tumor suppressor p14ARF; 3) a putative Zn
finger and a binding site for the retinoblastoma protein Rb; and
4) a RING finger and an E3 ligase domain that are responsible
for the ubiquitination of p53 [2,3].
Recently, Nutlin-3, a small-molecule inhibitor of MDM-2, has
been developed [4]. Nutlin-3 binds to MDM-2, releasing p53
from negative control and leading to effective p53 stabilization
and activation in cells with wild-type, but not mutant or deleted,
p53 [4,5]. Of note, recent studies have demonstrated that
Nutlin-3, used alone or in combination with chemotherapeutic
drugs, effectively increases the degree of apoptosis in acute
myeloid leukemia (AML), as well as in other hematologic malig-
nancies characterized by wild-type p53 [6–9].
Although the therapeutic effect of most conventional anti-
cancer drugs has been attributed for years to their ability to
induce apoptosis, it has been recognized that growth arrest
with morphologic features reminiscent of terminal maturation
constitutes an alternative drug-induced response program
controlled, at least in part, by the p53 pathway [10]. Thus, the
experiments illustrated in this study were designed to investi-
gate whether Nutlin-3, used alone or in combination with the
death-inducing ligand TNF-related apoptosis-inducing ligand
(TRAIL), was able to modulate the maturation of primary blasts
obtained by AML patients. Moreover, we have performed a
series of experiments in the p53/HL-60myeloblastic leukemia
cell line, which can be induced to undergo monocytic/granulo-
cytic terminal differentiation by a variety of chemical and bi-
ologic agents [11,12], and based on recent data demonstrating
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that Nutlin-3 is biologically active in both p53 wild-type and
p53-deleted or p53-mutated cells [13].
Materials and Methods
Patients and Cell Lines
Peripheral blood samples from 10 AML patients were
collected in heparin-coated tubes (Table 1) following their
provision of informed consent, in agreement with institutional
guidelines. The diagnosis of AML was made by periph-
eral blood and bone marrow morphology and immune phe-
notyping. These patients had been without prior therapy.
Peripheral blood mononuclear cells from AML patients
were isolated by gradient centrifugation with a lymphocyte
cell separation medium (Cedarlane Laboratories, Hornby,
Ontario), and freshly purified AML blasts were used imme-
diately after purification for different in vitro treatments. The
AML patients’ cells, as well as the p53/ HL-60 and p53
wild-type SKW6.4 cell lines, were cultured in RPMI 1640
(Gibco BRL, Grand Island, NY) supplemented with 10% fetal
calf serum (Gibco) and seeded at an optimal cell density of
0.8  106 to 1.0  106 cells/ml before treatments.
Primary AML blasts or HL-60 cells were treated with
predetermined optimal concentrations of Nutlin-3 (10 mM;
Sigma Aldrich, St. Louis, MO); recombinant TRAIL (0.1 mg/
ml), prepared as previously described [14]; or recombinant
tumor necrosis factor (TNF) a (10 ng/ml; R&D Systems,
Minneapolis, MIN), used either alone or in combination.
Assessment of Apoptosis and Cell Differentiation
At different times (1–3 days) posttreatment with Nutlin-3,
TRAIL, or TNF-a, both cytotoxicity and maturation-inducing
activity were assessed. In particular, samples were analyzed
by: 1) counting the total number of viable cells by trypan blue
dye exclusion; 2) evaluating the degree of apoptosis by
Annexin V/propidium iodide (PI) double staining and flow
cytometry and/or poly(ADP)ribose polymerase (PARP)
cleavage in Western blot analysis; as previously described
[15]; 3) monitoring the cell surface expression of CD14 and
CD11b myeloid antigens [16,17]; and 4) examining the
morphology of the cells by staining with May-Grunwald-
Giemsa solution followed by light microscopic examination.
In particular, for flow cytometry analyses, both Annexin
V–fluorescein isothiocyanate (FITC)/PI apoptosis kit and
CD11b and CD14 phycoerythrin-conjugated or FITC-conjugated
antibodies (Abs) were purchased from Immunotech (Mar-
seille, France). Nonspecific fluorescence was assessed by
using isotype-matched controls.
Flow cytometry analysis was also used to determine the
cell-cycle profile. HL-60 cells were incubated with 50 mM
BrdU (Sigma Aldrich) at 37jC for 1 hour. Anti-BrdU was
bound to BrdU incorporated into neosynthesized DNA, and
the complex was detected by FITC-conjugated secondary
Ab. Cells were stained with PI (50 mg/ml) and analyzed by
flow cytometry. To avoid nonspecific fluorescence from dead
cells, live cells were gated tightly using forward scatter and
side scatter. All flow cytometry analyses were performed
by using a FACScan flow cytometer and Lysis II software
(Becton Dickinson, San Jose, CA).
Western Blot Analysis and Immunoprecipitation
Cells were lysed in a buffer containing 50 mM Tris–HCl
pH 8.0, 250 mM NaCl, 0.5% NP-40, 2 mM sodium ortho-
vanadate, 1 mM phenylmethylsulfonyl fluoride, and 2 mg/ml
pepstatin, as described [18]. For Western blot analysis, 50
to 70 mg of protein was resolved on SDS polyacrylamide gels
and transferred to nitrocellulose membranes. Blots were in-
cubated with monoclonal Abs anti–MDM-2, anti-p53, anti–
DNA repair enzyme PARP (all from Santa Cruz Biotech-
nology, SantaCruz, CA), anti–Rbprotein (BectonDickinson),
or anti-tubulin (Sigma Aldrich) used for loading control.
Membranes were washed and further incubated for 1 hour
at room temperature with peroxidase–conjugated second-
ary Ab (Sigma Aldrich). Detection was then performed using
the Renaissance chemiluminescent ECL kit (NEN Dupont,
Boston, MA).
E2F1 was detected by immunoprecipitation experiments.
For this purpose, at least 5  106 to 10  106 cells/sample
were lysed in a buffer containing 50 mM Tris–HCl pH 7.5,
150 mM NaCl, 0.1% Tween 20, 0.5 mM EDTA, and the pro-
tease inhibitor cocktail P8340 (Sigma Aldrich). Cell lysates
were incubated with a polyclonal E2F1 Ab (Santa Cruz Bio-
technology) for 12 hours at 4jC before the addition of 40 ml
of A/G Sepharose beads (Santa Cruz Biotechnology) for
an additional 3 hours. Immunocomplex was washed thrice
with lysis buffer, loaded on 10% PAGE gels, and detected
by immunoblotting, as described above. In parallel, for each
experiment, equal fractions (5–10%) of cell lysates from un-
treated and Nutlin-treated cultures were analyzed by West-
ern blot analysis for tubulin levels, serving as controls of
immunoprecipitation inputs.
Protein levels were densitometrically analyzed by the
ImageQuant software (Molecular Dynamics, Sunnyvale,
CA). Multiple film exposures were used to verify the linearity
of the samples analyzed and to avoid saturation of the film.
Transfection Experiments
HL-60 cells (1.2  106 cells/0.5 ml) were mixed with 1 mg
of enhanced green fluorescence protein (EGFP) plasmid or
2 mg of small interfering RNA (siRNA) cocktails, transferred
Table 1. Clinical and Laboratory Features of AML Patients.
Patient No. AML p53 % Viable Cells + Nutlin-3*
1 M4 Wild type 67
2 M4/M5 Wild type 73
3 M5 Wild type 51
4 M5 Wild type 77
5 M4/M5 Deleted 93
6 M5 Wild type 23
7 M5 Wild type 58
8 M5 Wild type 54
9 M5 Wild type 60
10 M5 Wild type 55
*The percentage of viability was measured by trypan blue at 72 hours of
treatment.
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to a 2.0-mm electroporation cuvette, and nucleofected with
the Nucleofector Kit V (Amaxa, Cologne, Germany) using
the program T-019 of the Nucleofector device (Amaxa
Nucleofector II apparatus). After electroporation, cells were
immediately transferred to a complete RPMI supplemented
with 10% fetal calf serum and cultured at 37jC until analysis.
Transfection efficiency was monitored in each experiment
by scoring the percentage of EGFP-positive cells by flow cy-
tometry analysis.
siRNA were designed and manufactured by Ambion, Inc.
(Austin, TX) according to the method’s current guidelines for
effective knockdown. The following siRNA were tested: target
1 for E2F1, 5V-CCUGAUGAAUAUCUGUACUtt-3V (sense) and
5V-AGUACAGAUAUUCAUCAGGtg-3V (antisense); target 2
for E2F1, 5V-GGCCCGAUCGAUGUUUUCCtt-3V (sense) and
5V-GGAAAACAUCGAUCGGGCCtt-3V (antisense).
Ambion’s Silencer Negative Control siRNA were used to
demonstrate that the transfection did not induce nonspecific
effects on gene expression. A cocktail of two different nega-
tive control siRNA, each composed of a 19-bp scrambled
sequence with 3V dT overhangs, was used. The sequences
have no significant homology to any known gene sequence
from humans and have been previously tested for lack of
nonspecific effects on gene expression (Ambion).
Statistical Analysis
The results were evaluated using analysis of variance,
with subsequent comparisons by Student’s t test and Mann-
Whitney rank-sum test. Statistical significance was defined
as P < .05.
Results
Nutlin-3 Induces Variable Levels of Cytotoxicity
in Primary AML Blasts
To investigate the effect of Nutlin-3 on cell viability, AML
samples freshly isolated from patients free of therapy were
incubated in vitro with predetermined optimal concentrations
of Nutlin-3 (10 mM) and were assayed for viability by trypan
blue dye exclusion at 72 hours of treatment (Table 1). During
this time frame, the number of viable cells in untreated
cultures remained relatively constant, never dropping below
70% compared to the cell number seeded at time 0 (1 
106 cells/ml). On Nutlin-3 treatment, a variable decrease
in cell viability (61 ± 18.5; mean ± SD of the percentage
of cell viability compared with untreated controls; Table 1)
was observed, with all patient samples being susceptible
to Nutlin-3 cytotoxicity, with the exception of patient 5. The
decrease in cell viability induced by Nutlin-3 was paralleled
by a concomitant increase in the percentage of apoptosis,
evaluated in terms of Annexin V–positive cells (data not
shown) and/or PARP cleavage (Figure 1) with respect to
control cultures.
As expected based on previous studies [4–9], on Western
blot analysis, Nutlin-3, efficiently, although variably, upregu-
lated p53 protein levels, as well as MDM-2, in all AML
samples, with the exception of patient 5 (Figure 1). The lack
of induction of p53 in response to Nutlin-3 observed in pa-
tient 5 (Figure 1) has been previously shown to be a char-
acteristic feature of tumor samples wherein p53 was deleted
[4–9].
Nutlin-3 Promotes Myeloid Maturation in Primary AML
Blasts Independently of Its Proapoptotic Activity
Because an alternative therapeutic strategy to the induc-
tion of apoptosis is to promote terminal growth arrest and
maturation of AML blasts, in the next experiments, we have
investigated whether Nutlin-3 was able to modulate the
phenotypic profile and morphology of AML cells that survived
Nutlin-3 cytotoxicity. Independently of the basal expression
of CD11b and CD14 antigens that was variable from sample
to sample (data not shown), Nutlin-3 treatment showed
a significant (P < .05) induction of both surface CD11b
and CD14 antigens at 72 hours (Figure 2A). It should be
noticed that CD14 represents an excellent marker of mono-
cytic maturation because it is undetectable on the surface
of monocyte precursors and increases dramatically during
their differentiation into monocytes [16]. Surface CD11b, par-
ticularly the b2 integrin CR3, is another classic marker of
myeloid differentiation that is involved in cell adhesion and
also functions as a complement receptor [17].
Flow cytometry results were confirmed by morphologic
analyses, which showed an increment of cells with mono-
cytic features following Nutlin-3 treatment (Figure 2B). It is
particularly noteworthy that the ability of Nutlin-3 to promote
myeloid maturation occurred also in the p53-deleted patient
sample (patient 5; Figure 2B), indicating that the promatu-
rative effect of Nutlin-3 was totally unrelated to its ability to
induce apoptotic cell death.
Nutlin-3 Promotes Maturation of the p53/ Myeloblastic
HL-60 Cell Line in an E2F1-Dependent Manner
The data obtained on primary AML blast samples sug-
gested that Nutlin-3 might affect myeloid maturation not only
in p53 wild-type cells but also in p53/ cells. To further
ascertain whether this biologic activity of Nutlin-3 occurred
independently of p53, the next experiments were performed
on the p53/ AML HL-60 cell line (Figure 3A). Nutlin-3 alone
did not induce a significant increase in apoptosis in HL-60
Figure 1. p53 and MDM-2 induction in response to Nutlin-3 in primary AML
cells. AML cells were left untreated or were incubated with Nutlin-3 (10 M)
before Western blot analysis. Reported here are representative samples
(samples 1, 3, 4, and 6) showing a variable induction of p53 and MDM-2, and
one sample (sample 5) showing a lack of induction of p53 and MDM-2. PARP
cleavage (arrowhead; 80-kDa cleaved form) was also analyzed as an apop-
totic marker. Tubulin staining is shown as loading control.
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cells (Figure 3B), in keeping with a central role of the p53
pathway in mediating the proapoptotic activity of Nutlin-3 [4–
9]. In spite of the lack of induction of cytotoxicity, treatment
with Nutlin-3 induced a progressive increase in the surface
expression of both CD11b and CD14 in p53/ HL-60 cells
(Figure 3C). Moreover, the ability of Nutlin-3 to upregulate
the surface levels of CD11b and CD14 in HL-60 was more
evident than in primary AML blasts, suggesting that this cell
line is a good model for the study of the maturational effects
of Nutlin-3.
Because previous studies have shown that differentiation
of HL-60 cells was accompanied by exit from the cell cycle
[11,12,16,17,19], the next experiments were performed to
investigate whether Nutlin-3 induced changes in the cell-
cycle distribution of HL-60 cells. As shown in Figure 4A,
Nutlin-3 induced a significant (P < .05) accumulation of
HL-60 in the G2/M phase of the cell cycle. The ability of
Nutlin-3 to promote the accumulation of HL-60 cells in the
G2/M phase was markedly different from the biologic ac-
tivity of other compounds, such as the natural compound
saucernetin-7, which promoted cell-cycle arrest in G0/G1
coupled to the monocytic maturation of HL-60 cells [19]. Be-
cause MDM-2 has been shown to modulate the levels of Rb
protein [20,21], the levels of this transcription factor were
analyzed by Western blot analysis (Figure 4B). At variance
with other maturational compounds, which induced a pro-
gressive increase in the hypophosphorylated form of Rb pro-
tein [19], Nutlin-3 decreased the total levels of Rb protein in
HL-60 cells (Figure 4B).
Besides interacting with p53 and Rb protein, MDM-2 also
interacts with other transcription factors, which play an im-
portant role in the regulation of cell-cycle progression and
maturation [2,3]. In particular, it has been recently shown
that Nutlin-3 induced the expression of E2F1 in cell lines
derived from solid tumors [13]. Therefore, we next investi-
gated the effect of Nutlin-3 on E2F1 expression in HL-60
cells. Because the amount of E2F1 in HL-60 and AML pa-
tient cell lysates was too low to be detected by Western blot
analysis on whole-cell lysates (data not shown), immuno-
precipitation assay was performed. As shown in Figure 4C,
Figure 2. Maturative effect of Nutlin-3 on AML cells. AML cells were left untreated or were incubated with Nutlin-3 (10 M) for 72 hours and then analyzed for the
surface expression of CD11b and CD14 myeloid antigens, by flow cytometry analysis, and for cell morphology, by microscopic examination. In (A), CD11b and
CD14 expression in Nutlin-3 – treated cultures was calculated as fold induction with respect to untreated control cultures, which were set to 1. Data are expressed
as the mean ± SD of the results obtained from all patients reported in Table 1. *P < .05. In (B), the effects of Nutlin-3 on the cell morphology and surface expression
of CD11b and CD14 in two representative (sample 2, p53 wild-type cells; sample 5, p53-deleted cells) AML patient samples are shown. Cytocentrifuged AML
samples were stained with May-Grunwald-Giemsa solution. Arrowheads identify AML cells with morphologic features of more mature cells (original magnification,
40). CD11b and CD14 surface expression is reported as the percentage of positive cells, and data are expressed as the mean ± SD of three independent
analyses. *P < .05.
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treatment with Nutlin-3 induced the accumulation of E2F1
protein in the p53/ HL-60 leukemic cell model. Of note, a
similar effect was observed in selected p53 wild-type AML
samples, for which a sufficient number of cells were available
for the performance of E2F1 immmunoprecipitation assay
(Figure 4C).
In an attempt to further elucidate the role of E2F1 in AML
maturation induced by Nutlin-3, we have used a gene
knockdown approach. The transfection procedure adopted
in these experiments allowed to efficiently transfect 40 ± 5%
of HL-60 cells (Figure 5A). HL-60 cells were transfected with
a cocktail of two siRNA specific for E2F1 or with control
scrambled siRNA; 48 hours after transfection, cultures were
either left untreated or exposed to Nutlin-3. The efficiency
and specificity of gene knockdown were documented by
the ability of E2F1 siRNA, but not scrambled siRNA, to re-
duce the induction of E2F1 protein by Nutlin-3 treatment
(Figure 5B). In parallel, we could demonstrate that transfec-
tion with E2F1 siRNA, but not with scrambled siRNA, signif-
icantly (P < .05) counteracted the promaturative activity of
Nutlin-3 evaluated in terms of CD14 and CD11b surface ex-
pression (Figure 5B).
Nutlin-3 Potentiates the Maturational Activity
of Recombinant TRAIL
Having previously demonstrated that the TNF family
member TRAIL promotes both apoptotic cell death and
maturation of the HL-60 myeloid cell line [22], the next
experiments were performed to evaluate the effects of the
combined treatment Nutlin-3 + TRAIL on both apoptosis and
myeloid maturation of HL-60 cells. As shown in Figure 6, A
and B, Nutlin-3 significantly (P < .05) enhanced the ability of
Figure 3. Maturative effect of Nutlin-3 on HL-60 cells. HL-60 cells were left untreated or were incubated with Nutlin-3 (10 M). (A) Western blot analysis of cell
lysates shows lack of p53 accumulation in HL-60 in response to Nutlin-3. Tubulin staining is reported as loading control. (B) Flow cytometry profiles after Annexin V/PI
staining show lack of apoptosis induction in response to Nutlin-3 in HL-60 cultures. For both Western blot analysis (A) and flow cytometry (B) experiments, p53 wild-
type SKW cells were analyzed in parallel as positive control. Results representative of three separate experiments are shown. (C) The time-dependent effect of
Nutlin-3 (10 M) on the surface expression of CD11b and CD14 on HL-60 cells was quantitatively evaluated by flow cytometry. Data are presented as the mean ±
SD of five independent experiments performed in duplicate. *P < .05.
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both TRAIL and TNF-a, the prototype member of the TNF
superfamily, to promote the maturation of HL-60 cells. Be-
sides the induction of maturation, it is also noteworthy that
TRAIL markedly (P < .05) induced the apoptosis of HL-60
cells, whereas neither Nutlin-3 nor TNF-a alone significantly
modulated the degree of apoptosis over the background
level (Figure 6C). However, although Nutlin-3 did not inter-
fere with the cytotoxic activity of TRAIL, TNF-a significantly
(P < .05) counteracted the ability of TRAIL to induce apop-
tosis (Figure 6C).
Discussion
Wehave here shown for the first time that the small-molecule
inhibitor of MDM-2 Nutlin-3 promotes the maturation of both
p53wild-type and p53/ leukemic cells along themyelocytic/
monocytic lineage. It is particularly remarkable that suchmat-
urational effect was dissociated from the ability of Nutlin-3 to
induce apoptosis in AML blasts. It should also be emphasized
that although previous studies of our and other groups have
demonstrated the inhibitory effects of Nutlin-3 on the survival
of different types of hematologicmalignancies, including AML
[5–9], this study represents a demonstration of the positive
regulative effect of Nutlin-3 on primary AML blasts and HL-60
leukemic cells. Thus, the ability of Nutlin-3 to promote the
Figure 4. Modulation of the cell cycle and induction of E2F1 transcription factor
by Nutlin-3. (A) Representative cell-cycle profile of HL-60, either left untreated or
treated with Nutlin-3, as analyzed by BrdU/PI staining. The distribution of cells in
different phases of the cell cycle was calculated from flow cytograms and
expressed as the percentage of the total population. Data are expressed as the
mean ± SD of the results from six independent experiments. (B) Western blot
analysis of total Rb protein levels in HL-60 whole-cell lysates. Tubulin staining is
shown as loading control. (C) HL-60 cells and AML samples were treated with
Nutlin-3 (10 M) for 24 hours before the analysis of the E2F1 transcription factor
by immunoprecipitation (IP) followed by immunoblotting (IB). Tubulin levels of a
fraction of the total material used are shown as the control of input lysates.
Figure 5. Nutlin-3 promotes HL-60 maturation through E2F1 induction. HL-60
cells were transfected with control scrambled (scr.) siRNA or E2F1 siRNA
and then either left untreated or exposed to Nutlin-3 for 36 hours. In (A), the
efficiency of transfection in each experiment was monitored by flow cytometry
analyses of EGFP-transfected HL-60 cells. Representative flow cytometry
profiles are shown. In (B), the efficiency and specificity of E2F1 knockdown
were documented by immunoprecipitation (IP) followed by immunoblotting
(IB). Tubulin levels of a fraction of the total material used are shown as the
control of input lysates. One of five experiments with similar results is shown.
In parallel, surface CD14 and CD11b expression was evaluated by flow
cytometry. Data are expressed as the mean ± SD of the results from three
independent experiments. *P < .05.
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myeloid maturation of both primary AML blasts and HL-60
cells envisions an additional role of Nutlin-3 as an antineo-
plastic agent, at least for certain types of AML. In fact,
induction of mortality by terminal differentiation represents
an alternative approach to the cytodestruction of cancer cells
by conventional antineoplastic agents and has important
biologic implications. Indeed, it indicates that the malignant
state is not an irreversible one and suggests that certain
Figure 6. Nutlin-3 enhances the maturational activity of both recombinant TRAIL and TNF-a on HL-60 cells. HL-60 cells were left untreated or were treated with
TRAIL (0.1 g/ml) and/or TNF-a (10 ng/ml), either alone or in combination with Nutlin-3 (10 M), for 24 hours and then analyzed by flow cytometry for the surface
expression of CD11b and CD14 (A and B), as well as for levels of apoptosis (C). In (A), data are expressed as the mean ± SD of six independent experiments
performed in duplicate. In (B), a representative experiment is shown; shadowed histograms represent cells stained with Abs specific for the indicated surface
antigens, whereas unshadowed histograms represent background fluorescence obtained from the staining of the same cells with isotype-matched control Abs. In
(C), apoptosis was quantitatively evaluated after Annexin V/PI staining. Data are presented as the mean ± SD of six independent experiments performed in
duplicate. *P < .05 with respect to treatment with TRAIL alone.
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leukemias may eventually be treated with agents that initiate
terminal maturation, presumably with less morbidity than that
produced by cytodestructive agents [23]. In this respect,
retinoid acids are well-known inducers of the granulocytic
differentiation of primary acute promyelocytic leukemia
blasts and leukemic cell lines, apparently acting through
transcriptional regulation of critical genes [24]. In fact, both
retinoids and vitamin D3 interact with nuclear receptors—
members of the steroid/thyroid hormone receptor superfam-
ily of transcription factors [25]. These are ligand-inducible
trans regulators that modulate the transcription of genes,
which play a central role in the control of cell growth and
differentiation by interacting with retinoic acid or vitamin D3
cis-acting DNA-responsive elements [24,25]. However, al-
though some retinoids are currently used in the treatment of
acute promyelocytic leukemia (the M3 type of AML), agonists
such as vitamin D3 (which are able to induce monocytic
differentiation in other subtypes of AML and, in particular, in
M4 and M5 types) did not demonstrate efficacy in clinical
trials performed in AML patients, mainly due to secondary
hypercalcemia, thus limiting the dose of vitamin D3 that could
be administered [26].
Similarly to previous studies [11,12,19], we have also
shown that the ability of Nutlin-3 to promote HL-60 matu-
ration was coupled to significant modifications in cell-cycle
regulation. However, although a cell-cycle block at the G0/G1
checkpoint has been previously reported [19], our current
study demonstrates that Nutlin-3 induced cell-cycle accumu-
lation in G2/M. Thus, Nutlin-3 appears to act differently on
the cell cycle of leukemic HL-60 cells, as also underlined by
the fact that although accumulation of HL-60 cells in G0/G1
was accompanied by accumulation of the hypophosphory-
lated form of Rb protein [19], Nutlin-3 induced the down-
regulation of Rb protein in HL-60 cells. In this respect, our
findings are in line with a recent study in which a similar
downregulation of Rb protein was observed by treatment
with Nutlin-3 cell lines derived from solid tumors [13].
It has been shown that the p53 tumor-suppressor gene is
involved in the differentiation of myeloid lineage [27–29] and
that overexpression of p53 in the HL-60 cell line is able to
induce differentiation along the granulocytic or monocytic
pathway [30,31]. However, these previous data cannot en-
tirely account for our present findings. In fact, we found that
Nutlin-3 induces the maturation of both p53 wild-type and
p53/ primary AML blasts, as well as of the p53/ HL-60
cell line. In an effort to elucidate the molecular mechanism
underlining the ability of Nutlin-3 to promote maturation even
in p53/ AML cells, we could demonstrate that Nutlin-3 in-
duced E2F1 transcription factor, a phenomenon anticipating
the differentiation of HL-60 cells. The ability of Nutlin-3 to
upregulate E2F1 was in line with the findings of Ambrosini
et al. [13], who found that in the p53/ HCT116 colon car-
cinoma cell line, Nutlin-3 disrupted the binding of E2F1 to
MDM-2 and induced the transcriptional activation of free
E2F1. However, Nutlin-3 induced the degradation of E2F1
in p53 wild-type cells. The interpretation of these findings
was that the loss of E2F1 expression following Nutlin-3 ther-
apy in p53 wild-type cells appears to be mediated by
increased ubiquitination and subsequent proteasomal deg-
radation, whereas in cells with nonfunctional p53 (p53/
HCT cells), Nutlin-3 decreases the ubiquitination of E2F1,
avoiding degradation by the proteasome and making it avail-
able for the transcriptional activation of E2F1-related pro-
apoptotic molecules. Taken together, the findings of Ambrosini
et al. [13] and our present data suggest that E2F1 might
substitute for p53 in mediating myeloid maturation in p53/
AML cells. Moreover, although Ambrosini et al. [13] have
described the need for simultaneous treatment with cisplatin
to observe an increase in E2F1 in the p53/HCT116 cell line,
we have shown that treatment with Nutlin-3 alone was suffi-
cient to induce E2F1 in the HL-60 cell model.
Although the E2F1 transcription factor has been shown
to promote either cell proliferation or apoptotic cell death,
in relationship with the cell context [30,31], studies per-
formed on E2F1/ knockout mice have unequivocally dem-
onstrated the development of a broad spectrum of tumors,
suggesting that E2F1 in vivo mainly functions as a tumor
suppressor. Furthermore, although the overexpression of
E2F1 in the p53/M1myeloblastic leukemia cell lines count-
eracts IL-6–driven terminal differentiation and maintains leu-
kemogenicity [32], knocked-down mice for E2F transcription
factors significantly impaired normal hematopoiesis, with
defects at the bone marrow level of both erythroid and mye-
loid lineages and with a reduced release of mature red blood
cells and macrophages [33].
In conclusion, our present study suggests that a therapeu-
tic regimen including Nutlin-3 (possibly in association with re-
combinant TRAIL) would optimize anticancer activity against
leukemic cells by a two-fold mechanism: cytotoxicity in p53
wild-type cells and induction of differentiation along the mono-
cytic lineage in both p53 wild-type and p53-deleted cells.
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